Market Research Logo

Iran Pharmaceuticals and Healthcare Report Q4 2017

BMI View:

The business environment in Iran will remain decidedly difficult, limiting the incentive formultinational drugmakers to invest in the country. As a consequence, we expect the country's competitivelandscape to evolve, with pharmaceutical imports gradually diminishing and domestic firms capturing alarger market share over a multi-year horizon.

Headline Expenditure Projections

Pharmaceuticals: IRR79.60trn (USD1.99bn) in 2016 to IRR90.80trn (USD2.33bn) in 2017; +14.1% inlocal currency terms and +17.0% in US dollar terms. Forecast unchanged from previous quarter.

Healthcare: IRR898.08trn (USD22.45bn) in 2016 to IRR1006.01trn (USD25.80bn) in 2017; +12.0% inlocal currency terms and +14.9% in US dollar terms. Forecast unchanged from previous quarter.

Latest Updates

In July 2017, Iran's Deputy Health Minister Dr. Bagher Larijani and a team of Iraqi medical officialsannounced an agreement to cooperate on several scientific projects. These include the construction ofIraq's first foreign medical university by the Tehran University of Medical Sciences in collaboration withthe Iraqi health ministry.


BMI Industry View
Table: Headline Pharmaceuticals & Healthcare Forecasts (Iran 2015-2021)
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2013-2021)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2013-2021)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2013-2021)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2013-2021)
Prescription Drug Market Forecast
Patented Drug Market Forecast
Generic Drug Market Forecast
OTC Medicine Market Forecast
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Iran 2015-2021)
Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2015-2021)
Industry Risk/Reward Index
MENA Pharmaceuticals & Healthcare Risk/Reward Index
Regulatory Review
Intellectual Property Issues
Pricing & Reimbursement Regime
Market Overview
Healthcare Sector
Table: Healthcare Resources (Iran 2011-2016)
Table: Healthcare Personnel (Iran 2011-2016)
Table: Healthcare Activity (Iran 2011-2016)
Research & Development
Clinical Trials
Epidemiology
Table: HIV/AIDS Prevalence In Iran
Competitive Landscape
Research-Based Industry
Table: Multinational Company Activity
Generic Drugmakers
Table: Leading Drug Manufacturers, Iran - To March 2009
Pharmaceutical Distribution
Table: Leading Distributors, Iranian - Year To March 2008
Pharmaceutical Retail Sector
Table: Tehran Stock Exchange - Listed Pharmaceutical Companies As Of November 2015
Company Profile
Caspian Tamin Pharmaceutical Company
Darou Pakhsh
Exir Pharmaceuticals
Pars Darou
Zahravi Pharmaceutical Company
Demographic Forecast
Table: Population Headline Indicators (Iran 1990-2025)
Table: Key Population Ratios (Iran 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Iran 1990-2025)
Table: Population By Age Group (Iran 1990-2025)
Table: Population By Age Group % (Iran 1990-2025)
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Table: Indicators - Rationale And Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report